MetaADEDB 2.0 @ LMMD
eluxadoline
(QFNHIDANIVGXPE-FNZWTVRRSA-N)
Structure
SMILES
COc1ccc(cc1C(=O)O)CN([C@H](c1ncc([nH]1)c1ccccc1)C)C(=O)[C@H](Cc1c(C)cc(cc1C)C(=O)N)N
Type(s)
Approved; Investigational
ATC code(s)
A07DA06
Molecular Formula:
C32H35N5O5
Molecular Weight:
569.651
Log P:
5.5596
Hydrogen Bond Acceptor:
9
Hydrogen Bond Donor:
4
TPSA:
164.63
CAS Number(s):
864821-90-9
Synonym(s)
1.
eluxadoline
2.
Viberzi
External Link(s)
MeSHC583636
PubChem Compound11250029
130406582
BindingDB50393723
50393720
ChEBI85980
CHEMBLCHEMBL2159122
DrugBankDB09272
DrugCentral5001
IUPHAR/BPS Guide to PHARMACOLOGY7691
KEGGdr:D10403
Therapeutic Target DatabaseD09ZXR
ZINC14210876
Adverse Drug Event(s)
NameNumber of ReportsReference(s)Data Source
1Abdominal PainFAERS: 241
Canada Vigilance: 1
23583433
26789872
27922029
CTD
Canada Vigilance
US FAERS
2PancreatitisFAERS: 219
Canada Vigilance: 2
26789872
27922029
CTD
Canada Vigilance
US FAERS
3ConstipationFAERS: 15226789872
27922029
CTD
US FAERS
4Drug ineffectiveFAERS: 119
Canada Vigilance: 8
Canada Vigilance
US FAERS
5Inappropriate schedule of drug administrationFAERS: 101US FAERS
6NauseaFAERS: 89
Canada Vigilance: 1
26789872
27922029
CTD
Canada Vigilance
US FAERS
7Sphincter of Oddi DysfunctionFAERS: 70US FAERS
8VomitingFAERS: 55US FAERS
9Contraindicated drug prescribedFAERS: 53US FAERS
10Wrong technique in product usage processFAERS: 51
Canada Vigilance: 1
Canada Vigilance
US FAERS
11DizzinessFAERS: 43US FAERS
12Incorrect dose administeredFAERS: 43US FAERS
13Contraindicated product administeredFAERS: 39US FAERS
14Feeling abnormalFAERS: 38
Canada Vigilance: 1
Canada Vigilance
US FAERS
15Chest PainFAERS: 35US FAERS
16Drug dose omissionFAERS: 35US FAERS
17PainFAERS: 29US FAERS
18MalaiseFAERS: 26US FAERS
19FatigueFAERS: 24US FAERS
20Back PainFAERS: 23US FAERS
21Abdominal discomfortFAERS: 18
Canada Vigilance: 1
Canada Vigilance
US FAERS
22Contraindicated product prescribedFAERS: 18US FAERS
23Drug prescribing errorFAERS: 18US FAERS
24FlatulenceFAERS: 17
Canada Vigilance: 1
Canada Vigilance
US FAERS
25Euphoric moodFAERS: 16US FAERS
26HeadacheFAERS: 16US FAERS
27Lipase increasedFAERS: 16US FAERS
28SomnolenceFAERS: 16US FAERS
29PruritusFAERS: 14US FAERS
30Inappropriate schedule of product administrationFAERS: 12US FAERS
31HypersensitivityFAERS: 11US FAERS
32Alanine Aminotransferase IncreasedFAERS: 10US FAERS
33DehydrationFAERS: 10US FAERS
34PalpitationsFAERS: 10US FAERS
35Drug ineffective for unapproved indicationFAERS: 9
Canada Vigilance: 1
Canada Vigilance
US FAERS
36DyspepsiaFAERS: 9US FAERS
37AnxietyFAERS: 8US FAERS
38AstheniaFAERS: 8US FAERS
39Chest discomfortFAERS: 7US FAERS
40Drug effect incompleteFAERS: 7US FAERS
41Intestinal ObstructionFAERS: 7US FAERS
42Musculoskeletal PainFAERS: 7US FAERS
43Pancreatic enzymes increasedFAERS: 7US FAERS
44Therapeutic response unexpectedFAERS: 7US FAERS
45UrticariaFAERS: 7US FAERS
46Weight decreasedFAERS: 7US FAERS
47Amylase increasedFAERS: 6US FAERS
48Aspartate Aminotransferase IncreasedFAERS: 6US FAERS
49Bowel movement irregularityFAERS: 6US FAERS
50Drug screen positiveFAERS: 6US FAERS
51Product dose omissionFAERS: 6US FAERS
52Abdominal rigidityFAERS: 5US FAERS
53Head discomfortFAERS: 5US FAERS
54HepatitisFAERS: 5US FAERS
55HypotensionFAERS: 5US FAERS
56Irritable Bowel SyndromeFAERS: 527647873
27922029
CTD
US FAERS
57MyalgiaFAERS: 5US FAERS
58Peripheral swellingFAERS: 5US FAERS
59ArthralgiaFAERS: 4US FAERS
60ChillsFAERS: 4US FAERS
61ColitisFAERS: 4US FAERS
62FlushingFAERS: 4US FAERS
63Limb discomfortFAERS: 4US FAERS
64Product prescribing errorFAERS: 4US FAERS
65TremorFAERS: 4US FAERS
66AmnesiaFAERS: 3US FAERS
67Blood alkaline phosphatase increasedFAERS: 3US FAERS
68BronchitisFAERS: 3US FAERS
69Burning sensationFAERS: 3US FAERS
70CholelithiasisFAERS: 3US FAERS
71Cold sweatFAERS: 3US FAERS
72DiscomfortFAERS: 3US FAERS
73DysphoniaFAERS: 3US FAERS
74Enzyme level increasedFAERS: 3US FAERS
75EructationFAERS: 3US FAERS
76ErythemaFAERS: 3US FAERS
77Expired product administeredFAERS: 3US FAERS
78Gastrointestinal PainFAERS: 3
Canada Vigilance: 1
Canada Vigilance
US FAERS
79Gastrointestinal sounds abnormalFAERS: 3US FAERS
80IleusFAERS: 3US FAERS
81Intentional product misuseFAERS: 3US FAERS
82LethargyFAERS: 3US FAERS
83Ocular icterusFAERS: 3US FAERS
84Product storage errorFAERS: 3US FAERS
85SyncopeFAERS: 3US FAERS
86Absent bowel movementFAERS: 2US FAERS
87Adverse eventFAERS: 2US FAERS
88AlopeciaFAERS: 2US FAERS
89Biliary ColicFAERS: 2US FAERS
90Biliary dilatationFAERS: 2US FAERS
91Blood potassium increasedFAERS: 2US FAERS
92CholangitisFAERS: 2US FAERS
93ChromaturiaFAERS: 2US FAERS
94Duodenal UlcerFAERS: 2US FAERS
95GastroenteritisFAERS: 2US FAERS
96Gastrointestinal inflammationFAERS: 2US FAERS
97Intentional dose omissionFAERS: 2US FAERS
98Lip swellingFAERS: 2US FAERS
99Muscle tightnessFAERS: 2US FAERS
100Musculoskeletal discomfortFAERS: 2US FAERS
101Myocardial InfarctionFAERS: 2US FAERS
102OverdoseFAERS: 2US FAERS
103Poor peripheral circulationFAERS: 2US FAERS
104Product use in unapproved indicationFAERS: 2US FAERS
105Product use issueFAERS: 2US FAERS
106Rectal dischargeFAERS: 2US FAERS
107SluggishnessFAERS: 2US FAERS
108StressFAERS: 2US FAERS
109Transaminases increasedFAERS: 2US FAERS
110Abdominal tendernessFAERS: 1US FAERS
111Activities of daily living impairedFAERS: 1US FAERS
112Acute kidney injuryFAERS: 1US FAERS
113Alcohol interactionFAERS: 1US FAERS
114Ammonia increasedFAERS: 1US FAERS
115AnorgasmiaFAERS: 1US FAERS
116AphasiaFAERS: 1US FAERS
117AtaxiaFAERS: 1US FAERS
118Bladder spasmFAERS: 1US FAERS
119Blood glucose increasedFAERS: 1US FAERS
120Blood potassium decreasedFAERS: 1US FAERS
121Blood urine presentFAERS: 1US FAERS
122Cardiac ArrestFAERS: 1US FAERS
123Cardiac infectionFAERS: 1US FAERS
124Cerebrovascular accidentFAERS: 1US FAERS
125Colonoscopy abnormalFAERS: 1US FAERS
126CryingFAERS: 1US FAERS
127DisabilityFAERS: 1US FAERS
128Disease complicationFAERS: 1US FAERS
129DisorientationFAERS: 1US FAERS
130DissociationFAERS: 1US FAERS
131Disturbance in sexual arousalFAERS: 1US FAERS
132Drug ToleranceFAERS: 1US FAERS
133Drug administration errorFAERS: 1US FAERS
134Drug effective for unapproved indicationFAERS: 1US FAERS
135Electrolyte imbalanceFAERS: 1US FAERS
136Epigastric discomfortFAERS: 1US FAERS
137EpistaxisFAERS: 1US FAERS
138Erectile dysfunctionFAERS: 1US FAERS
139Facial paralysisFAERS: 1US FAERS
140False positive investigation resultFAERS: 1US FAERS
141Feeling of body temperature changeFAERS: 1US FAERS
142FibromyalgiaFAERS: 1US FAERS
143Gallbladder painFAERS: 1US FAERS
144GastritisFAERS: 1US FAERS
145Gastrointestinal obstructionFAERS: 1US FAERS
146General physical condition abnormalFAERS: 1US FAERS
147General physical health deteriorationFAERS: 1US FAERS
148GlossitisFAERS: 1US FAERS
149Hepatic EncephalopathyFAERS: 1US FAERS
150Hepatitis AFAERS: 1US FAERS
151HungerFAERS: 1US FAERS
152HyperventilationFAERS: 1US FAERS
153Impaired driving abilityFAERS: 1US FAERS
154InfectionFAERS: 1US FAERS
155InflammationFAERS: 1US FAERS
156Intentional product use issueFAERS: 1US FAERS
157Intercepted product dispensing errorFAERS: 1US FAERS
158Intestinal PerforationFAERS: 1US FAERS
159Joint injuryFAERS: 1US FAERS
160Joint swellingFAERS: 1US FAERS
161Joint warmthFAERS: 1US FAERS
162Large intestine perforationFAERS: 1US FAERS
163LeukocytosisFAERS: 1US FAERS
164Lipase abnormalFAERS: 1US FAERS
165Lower respiratory tract infectionFAERS: 1US FAERS
166MalabsorptionFAERS: 1US FAERS
167Medication ErrorFAERS: 1US FAERS
168Memory impairmentFAERS: 1US FAERS
169MenorrhagiaFAERS: 1US FAERS
170Mouth swellingFAERS: 1US FAERS
171Multi-organ disorderFAERS: 1US FAERS
172Muscle FatigueFAERS: 1
Canada Vigilance: 1
Canada Vigilance
US FAERS
173Muscle RigidityFAERS: 1US FAERS
174Muscle strainFAERS: 1US FAERS
175Musculoskeletal stiffnessFAERS: 1
Canada Vigilance: 1
Canada Vigilance
US FAERS
176Nasal pruritusFAERS: 1US FAERS
177Neck PainFAERS: 1US FAERS
178NervousnessFAERS: 1US FAERS
179No adverse eventFAERS: 1US FAERS
180Oropharyngeal painFAERS: 1US FAERS
181Pancreatic Enzymes DecreasedFAERS: 1US FAERS
182Pancreatic PseudocystFAERS: 1US FAERS
183Personality ChangeFAERS: 1US FAERS
184PneumoniaFAERS: 1US FAERS
185Pre-existing condition improvedFAERS: 1US FAERS
186Prescription drug used without a prescriptionFAERS: 1US FAERS
187PresyncopeFAERS: 1US FAERS
188Product difficult to swallowFAERS: 1US FAERS
189Product dispensing errorFAERS: 1US FAERS
190Product prescribing issueFAERS: 1US FAERS
191Product taste abnormalFAERS: 1US FAERS
192Product use complaintFAERS: 1US FAERS
193Psychological TraumaFAERS: 1US FAERS
194Rash erythematousFAERS: 1US FAERS
195Respiratory FailureFAERS: 1US FAERS
196RetchingFAERS: 1US FAERS
197RhinitisFAERS: 1US FAERS
198RosaceaFAERS: 1US FAERS
199SepsisFAERS: 1US FAERS
200Septic ShockFAERS: 1US FAERS
201Sexual DysfunctionFAERS: 1US FAERS
202SinusitisFAERS: 1US FAERS
203Skin irritationFAERS: 1US FAERS
204Stevens-Johnson SyndromeFAERS: 1US FAERS
205SunburnFAERS: 1US FAERS
206SwellingFAERS: 1US FAERS
207TachycardiaFAERS: 1US FAERS
208Therapeutic product effect decreasedFAERS: 1US FAERS
209Therapeutic response delayedFAERS: 1US FAERS
210Therapy cessationFAERS: 1US FAERS
211ThirstFAERS: 1US FAERS
212Tongue discomfortFAERS: 1US FAERS
213Unevaluable eventFAERS: 1US FAERS
214Urinary IncontinenceFAERS: 1US FAERS
215Urinary RetentionFAERS: 1US FAERS
216Urinary hesitationFAERS: 1US FAERS
217Urinary tract infectionFAERS: 1US FAERS
218Viral upper respiratory tract infectionFAERS: 1US FAERS
219Visual ImpairmentFAERS: 1US FAERS
220Vitamin D DeficiencyFAERS: 1US FAERS
221Wrong drug administeredFAERS: 1US FAERS
222furuncleFAERS: 1US FAERS
223jaundiceFAERS: 1US FAERS
224Diarrhea23583433
25261794
26789872
CTD
225Pneumatosis intestinalisCanada Vigilance: 1Canada Vigilance
Powered by :

Page last updated at 2020-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 120236

Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.